Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Guide To Mitigating Risks Of Long-Acting Opioids

Executive Summary

Because registries could have an adverse impact on patient access to long-acting and extended-release opioids, FDA is proposing a Risk Evaluation and Mitigation Strategy for the drugs that focuses on educating prescribers and patients about proper prescribing and use of the painkillers. The goal for the REMS is to reduce addiction, unintentional overdose and death resulting from inappropriate prescribing, misuse and abuse of the LA/ER products. If that does not occur with the education programs, FDA leaves the door open for a more vigorous risk management program. Below is a summary of FDA's proposal.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS052393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel